Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Esperion Therapeutics, Inc. has received an average rating of "Moderate Buy" from five brokerages, with one hold and four buy recommendations.
• The company's stock has a 1-year target price averaging $7.00, despite recent adjustments from analysts lowering targets to as low as $4.00.
• Esperion reported a surprising earnings per share (EPS) of ($0.02), surpassing estimates, and had revenues of $82.39 million for the last quarter.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $7.00.

Several equities analysts recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Wall Street Zen downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.

Esperion Therapeutics Trading Up 1.4%

Shares of NASDAQ:ESPR traded up $0.03 on Monday, hitting $2.21. The company had a trading volume of 3,762,013 shares, compared to its average volume of 4,795,865. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $3.94. The stock has a market cap of $445.59 million, a price-to-earnings ratio of -4.51 and a beta of 0.82. The stock has a 50 day moving average price of $1.48 and a 200 day moving average price of $1.33.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. The business had revenue of $82.39 million for the quarter, compared to the consensus estimate of $62.55 million. Sell-side analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ESPR. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics during the second quarter worth about $25,000. North Star Investment Management Corp. bought a new stake in Esperion Therapeutics during the second quarter worth about $25,000. Meridian Wealth Management LLC bought a new stake in Esperion Therapeutics during the first quarter worth about $29,000. Synergy Asset Management LLC lifted its position in Esperion Therapeutics by 3,496.3% during the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 30,138 shares during the period. Finally, Boomfish Wealth Group LLC lifted its holdings in shares of Esperion Therapeutics by 29.5% in the second quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 10,309 shares during the last quarter. Institutional investors own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.